PILOT STUDY OF LANREOTIDE IN METASTATIC OR RECURRENT GRADE I-II HINDGUT NET
Phase of Trial: Phase IV
Latest Information Update: 19 Sep 2019
Price : $35 *
At a glance
- Drugs Lanreotide (Primary)
- Indications Neuroendocrine tumours
- Focus Therapeutic Use
- 17 May 2019 Planned primary completion date changed from 1 Feb 2019 to 1 Feb 2020.
- 15 Jan 2018 Status changed to recruiting.
- 21 Mar 2017 New trial record